IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting now · Phase 1

Conditions studied: Advanced Clear Renal Cell Carcinoma, Adult

In brief

This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma

Key facts

Study ID

NCT06819293

Run by

Grit Biotechnology

People needed

12

Starts

2024-12-06

Expected to finish

2027-12-07

Last updated by the study team

2026-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
• Age ≥18 years old;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Expected survival time of ≥ 3 months;

You may not qualify if…

• CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS.
• Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects
• Have experienced myocardial infarction or unstable angina within the 6 months prior to screening
• Pleural effusion requiring drainage for symptom management within 28 days prior to screening

Where it is running

• Tongji hospital, Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.